Prescription drug · NDA
Faslodex (fulvestrant) NDC 0310-0720
Fulvestrant 50 mg/mL · Injection · Intramuscular · AstraZeneca Pharmaceuticals LP
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0310-0720-10 | 00310072010 | 2 SYRINGE, GLASS in 1 CARTON (0310-0720-10) / 5 mL in 1 SYRINGE, GLASSMarketed from Nov 1, 2010 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Faslodex
- Generic name (nonproprietary)
- fulvestrant
- Active ingredients
- Fulvestrant — 50 mg/mL
- Dosage form
- Injection
- Route
- Intramuscular
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 021344
- Marketing start
- Listing expires
- Other FDA classes
- Estrogen Receptor Antagonists (Mechanism)Selective Estrogen Receptor Modulators (Mechanism)
- Identifiers
- Product ID 0310-0720_9541dd80-09f9-4d3c-bb2a-fc354e198a2eSPL ID 9541dd80-09f9-4d3c-bb2a-fc354e198a2eSPL set ID 83d7a440-e904-4e36-afb5-cb02b1c919f7RxCUI 727762, 727954UNII 22X328QOC4
- Pharmacologic class
- Estrogen Receptor Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N400310072010followed by a unit qualifier and the quantityPackage 00310-0720-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Monotherapy FASLODEX is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy FASLODEX is indicated for the treatment of: • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer …
Excerpt only. Read the full label for complete information.